[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"axial-spondyloarthritis-non-radiographic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:axial-spondyloarthritis-non-radiographic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,71,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638927","phase-4-effectiveness-and-safety-of-acemetacin-in-active-axial-spondyloarthritis-a-real-world-study-100638927",false,"NCT07582146","Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study","Effectiveness and Safety of Acemetacin in Patients With Active Axial Spondyloarthritis: A Prospective, Multicenter, Observational Real-World Study","ARISE","Inclusion Criteria:\n\n* Subjects who fully understand the purpose and procedures of the trial and voluntarily sign the Informed Consent Form (ICF);\n* Subjects aged 18-65 years (inclusive), regardless of gender;\n* Meet the 2025 ASAS-SPARTAN Revised Classification Criteria for Axial Spondyloarthritis;\n* ASDAS score \\> 2.1.\n\nExclusion Criteria:\n\n* Subjects with known allergy to acemetacin, other NSAIDs, or any excipients;\n* Subjects with active gastrointestinal ulcer\u002Fbleeding, or a history of recurrent ulcer\u002Fbleeding;\n* Subjects with severe cardiac or renal dysfunction, or hepatic dysfunction;\n* Subjects with ulcerative colitis or Crohn's disease;\n* Subjects who received systemic glucocorticoids or intra-articular glucocorticoid injections within 3 months prior to the study start;\n* Subjects who received targeted therapy within 3 months prior to the study start;\n* Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study.","ALL","18 Years","65 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this observational study is to evaluate the effectiveness and safety of acemetacin in adults (18-65 years) with active axial spondyloarthritis (axSpA) who meet the 2025 ASAS-SPARTAN revised classification criteria and have an ASDAS score greater than 2.1.\n\nThe main questions this study aims to answer are:\n\n* Does acemetacin reduce overall pain assessed by visual analog scale (VAS) after 4 weeks of treatment?\n* What proportion of patients achieve clinical remission (ASDAS ≤1.3) or low disease activity (1.3\\\u003CASDAS≤2.1) at week 4?\n* What medical problems (side effects) occur during acemetacin treatment, with particular attention to gastrointestinal and cardiovascular events?\n\nParticipants will:\n\n* Undergo screening assessments including blood tests, imaging of the sacroiliac joints (MRI, CT, X-ray), and physical examination within 7 days before starting treatment\n* Take acemetacin 90 mg by mouth once daily for 4 weeks\n* Complete a phone follow-up at week 2 and an in-clinic visit at week 4\n* Have pain scores, disease activity measures (ASDAS, BASDAI, BASFI, ASAS HI, BASMI), and laboratory tests (CRP, ESR) recorded at each visit\n* Be monitored for adverse events throughout the treatment period",[28,29,30],"Axial Spondyloarthritis","Axial Spondyloarthritis, Non-Radiographic","Ankylosing Spondylitis (AS) \u002F Radiographic Axial SpA (r-axSpA)",[32,28,33,34],"Acemetacin","NSAIDs","Real-World Study","NOT_YET_RECRUITING","2026-05-06",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":22},"2026-04",{"date":43,"type":22},"2026-12",{"name":45,"class":46},"Chinese PLA General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100619800","phase-3-a-study-to-evaluate-the-efficacy-and-safty-of-608-in-patients-with-non--radiographic-axial-spondyloarthritis-nr-axspa-100619800","NCT07349329","A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)","A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)","Inclusion Criteria:\n\n1. Female and male patients at least 18 years of age at the time of screening.\n2. Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria\n3. Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)\n4. Total back pain as measured by NRS ≥ 4 at baseline\n\nExclusion Criteria:\n\n1. Patients with other uncontrolled active inflammatory diseases.\n2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance\n3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n4. History of cancer.\n5. Known or suspected history of immunosuppression.\n6. Known with allergic or intolerant to mometasone furoate spray or 608\u002Fplacebo.",{"count":56,"type":22},380,[58],"PHASE3","This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.",[29],"2026-01-09",{"date":63,"type":39},"2026-01-16",{"date":65,"type":22},"2026-03-09",{"date":67,"type":22},"2029-02-21",{"name":69,"class":70},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100578173","a-longitudinal-observational-study-to-evaluate-the-efficacy-of-movement-and-implement-concrete-movement-recommendations-with-the-help-of-mobility-tracking-with-smartwatches-in-subjects-with-axial-spondyloarthritis-100578173","NCT06807853","A LONGITUDINAL OBSERVATIONAL STUDY to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS with the HELP of MOBILITY TRACKING with SMARTWATCHES in SUBJECTS with AXIAL SPONDYLOARTHRITIS","SYMPTOM-ACCESSMENT in SUBJECTS with AXIAL SPONDYLOARTHRITIS with PATIENT-REPORTED OUTCOMES and MOBILITY TRACKING with SMARTWATCHES VIA SPECIALLY PROGRAMMED STUDY-APP to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS","SPARTAKUS","Inclusion Criteria:\n\n* Patients with Axial Spondyloarthritis\n* Patients do must have an own iPhone due to software reasons\n* do must be willing and able to wear a Smartwatch\n* do must be able to regularly fill out the PROs at home\n\nExclusion Criteria:\n\n* no iphone\n* no physical or mental Ability to wear a Smartwatch\n* no physical or mental Ability to regularly fill out the PROs at home",{"count":80,"type":22},50,"6 Months","OBSERVATIONAL","Axial spondyloarthritis (axSpa) is a chronic inflammatoric autoimmune disease of the back with a prevalence around 1,4% (1) . In patients decreased function and decreased quality of life as well as chronic pain are strong burdens . Despite modern treatments like biological agents just 25% of the patients are at remission (2) . Besides the pharmacological treatment physical activity is known to be very important to gain disease control. A low physical activity is related to a higher disease activity and a high physical activity to better disease control. Until now there is no structured capture of the daily movements of patients with axial spondylarthritis in clinical practice. Our goal is to analyse the relationship between movement and disease activity and to implement concrete recommendations for movement in patients with axSpa.\n\nThe primary objective of the study is to investigate which type, frequency and intensity of movement are helpful in gaining and remaining disease control in patients with axSpa.\n\nMethods This monocentric longitudinal study recordes movement, sport and physical parameters like heart frequency and heart rate variability through an observational period of 6 month via smartwatch. Meanwhile we record disease activity, pain and functional outcomes with regular surveys every two weeks. Patients in every phase of disease are eligible for inclusion, but they do must have an own iPhone due to software reasons. Data is collected in a specially programmed study-app. Fifty participants will be included in this study. Until now we have 24 patients included since april 2024. Patients come to clinic every 3 month as this is our standard in outclinic patients. We than do anamnesis and a physical examination. After the study period of 6 month we transmit the mobility and disease-related data of the surveys of the patients mobile device to our system.\n\nThe primary endpoint is to find exact recommendations for concrete movement in patients with axSpa.\n\nSo this is the first study that wants to give concrete recommendations for movement in patients with axSpa with the help of mobility tracking with smartwatches. This could help to prevent flares and also to recover quicker from a flare.\n\n1. López-Medina und Moltó, \"Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis\".\n2. Pina Vegas u. a., \"Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort\".",[28,85,86,87,88,29,89],"Axial Spondyloarthritis (AxSpA)","Axial Spondylarthritis (r-axSpA)","Axial Spondyloarthopathy","Axial Spondyloarthritis and Ankylosing Spondylitis","Axial and Peripheral Spondyloarthritis",[91,92,93,94,95,96,97],"Mobility Tracking","Patient-Reported Outcomes (PROs)","Disease Activity","Smartwatch","Study-App","Mobile Device","Movement Recommedations","RECRUITING","2025-02-13",{"date":101,"type":39},"2025-02-18",{"date":103,"type":39},"2024-04-01",{"date":105,"type":22},"2025-11",{"name":107,"class":46},"University of Bonn",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":116,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100560454","osteosarcopenia-in-axial-spondyloarthritis-100560454","NCT06577350","Osteosarcopenia in Axial Spondyloarthritis","The Frequency of Osteosarcopenia and Its Relationship With Demographic and Clinical Factors in Axial Spondyloarthritis","Inclusion Criteria:\n\nPatient group:\n\n* Participants with a diagnosis of AxSpA: Participants with diagnosis of Ankylosing Spondylitis according to the modified New York criteria and participants with diagnosis of non-radiographic Spondyloarthritis (SpA) according to the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria.\n* Aged 18-65 years\n* Who gave consent to participate in the study\n\nHealthy control group:\n\n* Age- and gender-matched healthy participants (age 18-65)\n* Who gave consent to participate in the study\n\nExclusion Criteria:\n\n1. Systemic high-dose steroid use (\\>5mg\u002Fday of prednisone for more than 3 months)\n2. Possible other causes of secondary sarcopenia (uncontrolled diabetes, chronic heart failure, thyroid\u002Fparathyroid disease, chronic renal failure, chronic liver failure)\n3. Hand-related disorders\u002Fdiseases that could affect the healthy assessment of grip strength\n4. Use of any medication that could potentially affect the bone metabolism (bisphosphonates, teriparatide, anticonvulsants, heparin, and anticoagulants)\n5. Psoriasis, inflammatory bowel disease\n6. Infection in the thigh area where ultrasonographic evaluation will be performed\n7. Body weight over 100 kg (contraindication to be positioned in the BMD device)\n8. Presence of malnutrition (individuals scoring 11 or below on the Mini Nutritional Assessment-Short Form (MNA))",true,{"count":117,"type":22},97,"Axial spondyloarthritis is a chronic inflammatory disease affecting the spine, sacroiliac joints, entheses, and sometimes peripheral joints with a close link to HLAB27. Typical features include inflammatory back pain, limited spinal mobility, and sacroiliitis. The term axial spondyloarthritis (AxSpA) includes both Ankylosing Spondylitis (AS) where sacroiliitis is diagnosed by X-rays, and non-radiographic AxSpA, where sacroiliitis is diagnosed via magnetic resonance imaging (MRI).\n\nOsteoporosis is common in AS patients, and sarcopenia may also develop due to inflammation and immobilization. Osteosarcopenia, the co-occurrence of osteoporosis and sarcopenia, might have an impact on morbidity and mortality of AxSpA patients.\n\nThis cross-sectional study aims to determine the frequency of osteosarcopenia in AxSpA patients and to investigate its relationship with various demographic and clinical factors. A control group with similar age and gender distribution will be recruited to evaluate osteosarcopenia. Our hypothesis is that osteosarcopenia will be more frequent in the AxSpA group compared to the control group. The study will also identify the demographic and clinical factors associated with osteosarcopenia in AxSpa.",[28,120,29,121,122,123],"Ankylosing Spondylitis","Osteoporosis","Sarcopenia","Osteosarcopenia",[28,120,125,121,122,123],"Non-Radiographic Axial Spondyloarthritis","2024-08-28",{"date":128,"type":39},"2024-08-29",{"date":130,"type":39},"2023-09-01",{"date":132,"type":22},"2025-04",{"name":134,"class":46},"Ankara University"]